ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Gramm-Rudman Cut Facing NCI Could Take $85 Million

October 20, 1989

New Data Support Claims That Costs Are Higher For Protocol Patients

August 31, 1984

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013

Abigail Alliance says statisticians usurped control of oncology. Milken’s optimism fuels the movement.

August 5, 2005

Drasga and Einhorn Respond to Single Payer Proposal Rebuttal

February 14, 2014

Building Boom of Proton Beam Centers Flares Up in Washington and Baltimore

October 25, 2013